The effect of psoriasis treatment on body composition, components of metabolic syndrome and psoriatic arthritis

Abstract

Background and Design:Psoriasis is a chronic inflammatory immune-mediated skin disorder with unknown etiology. Chronic inflammation in psoriasis has a role in the development of metabolic and vascular disorders related with associating comorbidities. Recent studies have suggested a strong association between psoriasis and obesity, which is one of the components of metabolic syndrome, and emphasized the complex relationship of psoriasis treatment with psoriasis and body mass index (BMI). In this study, our aim was to investigate the effect of psoriasis treatment with methotrexate, cyclosporine and biological agents on body composition, comorbidities and associated laboratory findings. Materials and Methods: Seventy-nine patients treated with methotrexate, cyclosporin and biological agents were included in our study. Demographic characteristics, body composition analysis, psoriasis-related comorbidities and laboratory examinations were evaluated before and after 12 weeks of systemic treatment. Results: Comorbidities and metabolic syndrome tended to be more frequent in the anti-tumor necrosis factor alpha (anti-TNF-α)-treated group. Increase in body fat and weight detected in patients receiving biologic drug therapy. Conclusion:The results of our study showed that patients with severe psoriasis with longer disease duration were more likely to have metabolic syndrome because of severe and long-term inflammation in the pathogenesis of comorbidities. (Turkderm 2015; 49: 41-4)

Evaluation of Body Composition in Patients with Psoriasis

“…After three months of treatment, except for etanercept a significant increase in body weight and BMI values was determined in the groups using infliximab, adalimumab, methotrexate and cyclosporine [13]. In this study, the group with psoriasis was evaluated according to only topical and phototherapy-systemic treatment.…”